Putting Methylphenidate for Cancer-Related Fatigue to Rest?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38771985.
- Also identified by DOI 10.1200/JCO.24.00707 and PMC identifier 11520668.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the article that accompanies this editorial, Stone et al. present a randomized, double-blind, placebo-controlled trial of individually dose-titrated methylphenidate for treatment of fatigue in patients with advanced cancer, finding that methylphenidate, while safe and well-tolerated, was no more effective than placebo at relieving fatigue after 6 (±2) weeks. Future studies should consider the multifaceted nature of cancer-related fatigue, as well as the substantial placebo effects of psychostimulants, and may benefit from focusing on methylphenidate in combination with non-pharmacological interventions, or for fatigue with a predominant emotional or cognitive component.
Medical subject headings
- Methylphenidate
- Fatigue
- Neoplasms
- Central Nervous System Stimulants